# Cancer Therapeutics

> **NIH NIH P30** · STANFORD UNIVERSITY · 2024 · $55,542

## Abstract

PROJECT SUMMARY
The Cancer Therapeutics (CT) Program has been reconfigured from the previous Molecular Oncology Program
to unite an exciting new opportunity in drug development with ongoing research in the areas of biomarker design
and new diagnostic approaches to cancer, the ultimate objective being the development of clinical trials with high
impact for cancer patients with solid tumors. In conjunction with a University-wide initiative to enable drug
discovery to improve human health, the Stanford Cancer Institute (SCI) Strategic Plan has made the discovery
of new approaches to cancer treatment one of its major pillars. This new emphasis on drug development has
been enabled by the recruitment of Nathanael Gray, PhD, co-leader of the program and a pre-eminent
researcher in the development of novel therapeutic agents for cancer. Program co-leader, George W. Sledge,
MD, has more than three decades of experience as a clinical trialist involved in Phase I, II, and III trials, including
trials that have led to the FDA approval of new agents in breast cancer, as well as significant experience in the
development of biomarkers for breast cancer. This complementary leadership team, in conjunction with a diverse
and talented program membership, integrates highly relevant basic science research with the development and
implementation of impactful clinical trials across the spectrum of solid tumors. With the addition of 24 new
members since the last review, the 67 program members represent 3 schools and 18 departments across the
University and are supported by peer-reviewed research totaling $10M, including 20 R01s. Peer-reviewed
funding consists of $4.8M from the NCI, other NIH support amounts to $3.3M, and other peer-reviewed support
to $1.8M. CT program members are highly motivated and interactive in their goal of bringing forward novel
therapeutic options for cancer patients. Since 2015, members of the CT Program have published 814
manuscripts. Of these, 21% represent intra-programmatic, 42% represent inter-programmatic, and 95%
represent multi-institutional collaborations. The SCI has fostered the CT Program by greatly expanding its
potential through new recruitments, providing innovation fund support for new projects, as well as funds for
retreats and seminars. SCI’s support has been instrumental in promoting intra- and inter-programmatic
collaborations and in the planning and submission of two SPORE applications. The CT Program plans to
accelerate investment in the discovery of new small molecule therapeutics, expand our clinical Early Drug
Development Program, and pioneer high-impact clinical trials.

## Key facts

- **NIH application ID:** 10887418
- **Project number:** 5P30CA124435-16
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** NATHANAEL Schiander GRAY
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $55,542
- **Award type:** 5
- **Project period:** 2007-06-04 → 2027-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10887418

## Citation

> US National Institutes of Health, RePORTER application 10887418, Cancer Therapeutics (5P30CA124435-16). Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/grant/nih/10887418. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*